



## Engineering Aptamers for Biomedical Applications

Guest Editor:

**Dr. Vittorio de Franciscis**

Istituto per l'Endocrinologia e  
Oncologia Sperimentale "G.  
Salvatore", Via Tommaso De  
Amicis 95 Via S. Pansini 5, 80145  
Naples, Italy

Deadline for manuscript  
submissions:

**closed (31 March 2018)**

### Message from the Guest Editor

Dear Colleagues,

This Special Issue, "Engineering Aptamers for Biomedical Applications", will mainly focus on the more recent advances in the development of highly stable and specific aptamers suitable as therapeutic and diagnostic agents.

The introduction of modifications in the nucleic acids backbone, the expansion of genetic variability in nucleobases and the generation of enzymes able to catalyze the synthesis of modified aptamers is revealing as invaluable advantage in the design of aptamer ligands in biomedicine. Aptamers obtained with nucleic acid variants exhibit high stability in circulating fluids, target binding affinity and specificity thus potentially improving their applicability as therapeutics and/or as diagnostic tools.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)